Hanly, Elyse K <br/><br/>
Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells.  [electronic resource] 

 -  Oncotarget  Feb 2016 
 - 8676-87 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.6779  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Apoptosis--drug effects<br/>Blotting, Western<br/>Carcinoma, Papillary--drug therapy<br/>Cell Proliferation--drug effects<br/>Drug Resistance, Neoplasm<br/>Humans<br/>Immunoprecipitation<br/>Indoles--pharmacology<br/>Mitogen-Activated Protein Kinase 1--metabolism<br/>Mitogen-Activated Protein Kinase 3--metabolism<br/>Phosphorylation<br/>Signal Transduction--drug effects<br/>Sulfonamides--pharmacology<br/>TOR Serine-Threonine Kinases--metabolism<br/>Thyroid Neoplasms--drug therapy<br/>Tumor Cells, Cultured<br/>Vemurafenib